Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind Randomized Placebo-controlled Parallel Design Multicenter Phase IIIb Study of the Effect of Sodium Zirconium Cyclosilicate (SZC) on Serum Potassium and Serum Bicarbonate in Patients With Hyperkalemia and Metabolic Acidosis Associated With Chronic Kidney Disease (NEUTRALIZE)

NCT04727528 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04727528
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04727528 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind Randomized Placebo-controlled Parallel Design Multicenter Phase IIIb Study of the Effect of Sodium Zirconium Cyclosilicate (SZC) on Serum Potassium and Serum Bicarbonate in Patients With Hyperkalemia and Metabolic Acidosis Associated With Chronic Kidney Disease (NEUTRALIZE)
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Terminated
Start date
March 22, 2021
Completion date
September 14, 2022
Enrollment
39 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease, hyperkalaemia, metabolic acidosis